English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 31 Help

Selected(0)Clear Items/Page:    Sort:
Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy Journal article
Mo, Hualong, Liu, Jie Ying, Su, Zhengxi, Zhao, Deng Gao, Ma, Yan Yan, Zhang, Kun, Wang, Qi, Fu, Chun, Wang, Yao, Chen, Meiwan, Hu, Burong. Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy[J]. European Journal of Medicinal Chemistry, 2024, 277, 116765.
Authors:  Mo, Hualong;  Liu, Jie Ying;  Su, Zhengxi;  Zhao, Deng Gao;  Ma, Yan Yan; et al.
Favorite | TC[WOS]:1 TC[Scopus]:1  IF:6.0/6.1 | Submit date：2024/09/03
Antitumor  Hdac  Isoalantolactone  Self-assembled Nanoparticles  Stat3  
Involvement of M2 macrophages polarization in PM2.5-induced COPD by upregulating MMP12 via IL4/STAT6 pathway Journal article
Guo, Xiaolan, Yang, Siqi, Zhu, Huijuan, Liu, Fengdong, Li, Kai, Li, Guojun, Lin, Yuyin, Yu, Hongjiao, Qiu, Wenxi, Xu, Hao, Liu, Qiao, Xie, Xinran, Sun, Yaowei, Zheng, Peiji, Chen, Bingjie, Liu, Zihan, Yuan, Xiaopeng, Peng, Shuyi, Bi, Xinhui, Yang, Jingwen, Shao, Ning yi, Dai, Jianwei. Involvement of M2 macrophages polarization in PM2.5-induced COPD by upregulating MMP12 via IL4/STAT6 pathway[J]. Ecotoxicology and Environmental Safety, 2024, 283, 116793.
Authors:  Guo, Xiaolan;  Yang, Siqi;  Zhu, Huijuan;  Liu, Fengdong;  Li, Kai; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:6.2/6.3 | Submit date：2024/08/05
Copd  Il-4/stat6 Pathway  M2 Macrophage Polarization  Mmp12  Pm2.5  
Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma Journal article
Zhang, Qi Yi, Ding, Wen, Mo, Jian Shan, Ou-yang, Shu Min, Lin, Zi You, Peng, Ke Ren, Liu, Guo Pin, Lu, Jin Jian, Yue, Pei Bin, Lei, Jin Ping, Wang, Yan Dong, Zhang, Xiao Lei. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma[J]. ACTA PHARMACOLOGICA SINICA, 2024.
Authors:  Zhang, Qi Yi;  Ding, Wen;  Mo, Jian Shan;  Ou-yang, Shu Min;  Lin, Zi You; et al.
Favorite | TC[WOS]:5 TC[Scopus]:6  IF:6.9/7.6 | Submit date：2024/05/16
Acquired Sorafenib-resistance  Antisense Oligonucleotide  Hepatocellular Carcinoma  Stat3  
Ruyong formula improves thymus function of CUMS-stimulated breast cancer mice Journal article
He, Bingqian, Guo, Wenqin, Shi, Rongzhen, Hoffman, Robert D., Luo, Qihan, Hu, Yuanjia, Guo, Jianli. Ruyong formula improves thymus function of CUMS-stimulated breast cancer mice[J]. Journal of Ethnopharmacology, 2024, 319(1), 117164.
Authors:  He, Bingqian;  Guo, Wenqin;  Shi, Rongzhen;  Hoffman, Robert D.;  Luo, Qihan; et al.
Adobe PDF | Favorite | TC[WOS]:0 TC[Scopus]:0  IF:4.8/4.8 | Submit date：2024/01/02
Ruyong Formula  Breast Cancer  Epithelial Mesenchymal Transition  Cums  Thymus Function  Jak2/stat3/pi3k Pathway  
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia Journal article
Mo, Jianshan, Deng, Lin, Peng, Keren, Ouyang, Shumin, Ding, Wen, Lou, Linlin, Lin, Ziyou, Zhu, Jianzheng, Li, Jingwei, Zhang, Qiyi, Wang, Pengyan, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Lu, Jin Jian, Zhu, Kai, Zheng, Yongjiang, Wang, Yuanxiang, Zhang, Xiaolei. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia[J]. Journal of Hematology & Oncology, 2023, 16(1), 15.
Authors:  Mo, Jianshan;  Deng, Lin;  Peng, Keren;  Ouyang, Shumin;  Ding, Wen; et al.
Favorite | TC[WOS]:15 TC[Scopus]:14  IF:29.5/26.9 | Submit date：2023/03/06
Aml  Immunotherapy  Stat3 Inhibitor  Vista  
Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells Journal article
HE, Xinyu, FU, Jiarui, LYU, Wenyu, HUANG, Muyang, MO, Jianshan, CHENG, Yaxin, XU, Yulian, ZHENG, Lijun, ZHANG, Xiaolei, QI, Lu, ZHANG, Lele, ZHENG, Ying, HUANG, Mingqing, NI, Lin, LU, Jinjian. Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells[J]. Chinese Journal of Natural Medicines, 2023, 21(11), 842-851.
Authors:  HE, Xinyu;  FU, Jiarui;  LYU, Wenyu;  HUANG, Muyang;  MO, Jianshan; et al.
Favorite | TC[WOS]:1 TC[Scopus]:1  IF:4.0/3.7 | Submit date：2024/01/10
Bulbocodin c  Bulbocodin d  Cancer  Erk  Natural Products  Stat3  
The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone Journal article
Shao, Zeyang, Wang, Heng, Ren, Haiyan, Sun, Yinxiang, Chen, Xiuping. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone[J]. Molecules, 2023, 28(15).
Authors:  Shao, Zeyang;  Wang, Heng;  Ren, Haiyan;  Sun, Yinxiang;  Chen, Xiuping
Favorite | TC[WOS]:12 TC[Scopus]:10  IF:4.2/4.6 | Submit date：2024/01/10
cancer  napabucasin  NQO1  STAT3  
Reactive oxygen species and nitric oxide scavenging nanoparticles alleviating rheumatoid arthritis through adjusting the seeds and growing soils Journal article
Peng Hua, Ruifeng Liang, Yanbei Tu, Yuying Yin, Man-Kay Law, Meiwan Chen. Reactive oxygen species and nitric oxide scavenging nanoparticles alleviating rheumatoid arthritis through adjusting the seeds and growing soils[J]. Acta Pharmaceutica Sinica B, 2023, 13(12), 5016-5029.
Authors:  Peng Hua;  Ruifeng Liang;  Yanbei Tu;  Yuying Yin;  Man-Kay Law; et al.
Favorite | TC[WOS]:8 TC[Scopus]:9  IF:14.7/14.1 | Submit date：2023/08/21
Anti-inflammatory  Bilirubin  Cartilage Protection  Jak-stat Pathway  Notopterol  O-phenylenediamine  Rheumatoid Arthritis  Ros And No Scavenging  
The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone Journal article
Zeyang Ahao, Heng Wang, Haiyan Ren, Yinxiang Sun, Xiuping Chen. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone[J]. Molecules, 2023, 28(15), 5678.
Authors:  Zeyang Ahao;  Heng Wang;  Haiyan Ren;  Yinxiang Sun;  Xiuping Chen
Adobe PDF | Favorite | TC[WOS]:12 TC[Scopus]:10  IF:4.2/4.6 | Submit date：2023/08/17
Cancer  Napabucasin  Nqo1  Stat3  
Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer Journal article
Lu, Jiaye, Li, Jingwei, Lin, Ziyou, Li, Huaxuan, Lou, Linlin, Ding, Wen, Ouyang, Shumin, Wu, Yonghui, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Wang, Yuanxiang, Liu, Peiqing, Lu, Jinjian, Zhang, Jian, Feng, Weineng, Zhang, Xiaolei. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer[J]. Cancer Letters, 2023, 564, 216205.
Authors:  Lu, Jiaye;  Li, Jingwei;  Lin, Ziyou;  Li, Huaxuan;  Lou, Linlin; et al.
Favorite | TC[WOS]:25 TC[Scopus]:25  IF:9.1/8.3 | Submit date：2023/07/20
Acquired Tki Resistance  Cd47  Lung Cancer  Stat3  Tams